PMID- 38125558
OWN - NLM
STAT- MEDLINE
DCOM- 20240112
LR  - 20240129
IS  - 2046-1402 (Electronic)
IS  - 2046-1402 (Linking)
VI  - 12
DP  - 2023
TI  - The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly 
      dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
PG  - 914
LID - 10.12688/f1000research.128441.2 [doi]
LID - 914
AB  - BACKGROUND: Type 2 Diabetes Mellitus (T2DM) is a highly prevalent disease 
      worldwide and in Colombia, representing one of the main causes of death and 
      placing a considerable burden on healthcare systems. 13 classes of drugs are 
      approved for the treatment of T2DM, with Glucagon-like Peptide-1 (GLP-1) receptor 
      agonists being a first-line treatment option for patients with or at high risk of 
      certain cardiovascular diseases and chronic kidney disease. The objective of this 
      study is to conduct a short-term cost-effectiveness analysis of once-weekly 
      semaglutide versus once-weekly dulaglutide in Colombian adults with T2DM, from a 
      third-party payer perspective. METHODS: Numbers needed to treat were calculated 
      for different single and composite endpoints of the SUSTAIN 7 trial, annual costs 
      for once weekly semaglutide 1.0 mg and dulaglutide 1.5 mg were extracted from the 
      public SISMED database. With these inputs a cost of control model was developed, 
      to obtain the annual cost of bringing one T2DM patient to relevant clinical 
      outcomes by using semaglutide or dulaglutide. RESULTS: Semaglutide was considered 
      cost-effective compared to dulaglutide across all pre-specified endpoints, even 
      in the different scenarios evaluated in the sensitivity analyses, and in a 
      particularly pronounced manner for weight loss outcomes. Semaglutide at a dose of 
      1.0 mg once-weekly was cost-effective compared to dulaglutide 1.5 mg across all 
      outcomes in the short-term, making it an appropriate first-line choice in the 
      treatment of T2DM when deciding between these two GLP-1 receptor agonists. 
      CONCLUSIONS: This is the first short-term cost-effectiveness study of semaglutide 
      and dulaglutide in T2DM Colombian patients. Our modeled results suggest that 
      once-weekly semaglutide represents a cost-effective option for treating 
      individuals with T2DM in Colombia who are not achieving glycaemia control with 
      metformin, and it would be expected to improve HbA1C, promote greater weight loss 
      and reduce costs from a third-payer perspective compared with treatment with 
      dulaglutide.
CI  - Copyright: (c) 2023 Liebisch-Rey H et al.
FAU - Liebisch-Rey, Hans
AU  - Liebisch-Rey H
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Suarez-Chacon, Andrea-Marcela
AU  - Suarez-Chacon AM
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Fuentes, Yuli-V
AU  - Fuentes YV
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Blanco, Jhosep
AU  - Blanco J
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Kock, Joshua
AU  - Kock J
AD  - Department of Epidemiology, Faculty of Medicine, Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Lechtig-Wassermann, Sharon
AU  - Lechtig-Wassermann S
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
FAU - Bustos, Rosa Helena
AU  - Bustos RH
AD  - Evidence-Based Therapeutics Group, Department of Clinical Pharmacology, Faculty 
      of Medicine, Universidad de La Sabana and Clinica Universidad de La Sabana, Chia, 
      Cundinamarca, 140013, Colombia.
LA  - eng
PT  - Journal Article
DEP - 20231211
PL  - England
TA  - F1000Res
JT  - F1000Research
JID - 101594320
RN  - WTT295HSY5 (dulaglutide)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Colombia
MH  - Cost-Effectiveness Analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Weight Loss
MH  - Clinical Trials as Topic
PMC - PMC10730985
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Dulaglutide
OT  - Pharmacoeconomic
OT  - Semaglutide
COIS- No competing interests were disclosed.
EDAT- 2023/12/21 06:42
MHDA- 2023/12/22 06:42
PMCR- 2023/12/11
CRDT- 2023/12/21 04:13
PHST- 2023/12/05 00:00 [accepted]
PHST- 2023/12/22 06:42 [medline]
PHST- 2023/12/21 06:42 [pubmed]
PHST- 2023/12/21 04:13 [entrez]
PHST- 2023/12/11 00:00 [pmc-release]
AID - 10.12688/f1000research.128441.2 [doi]
PST - epublish
SO  - F1000Res. 2023 Dec 11;12:914. doi: 10.12688/f1000research.128441.2. eCollection 
      2023.